ARPA-H Backs Custom RNA Therapy Biotechs
By Editor • September 2, 2026 • 1 min read
In a significant move, ARPA-H is providing funding to biotechnology firms focused on developing personalized RNA therapies. This initiative aims to advance innovative treatments tailored to individual patient needs.
Meanwhile, UniQure has applied for FDA and UK MHRA approval for AMT-130, a promising therapy for Huntington's disease, marking a crucial step in its development.
Source: www.statnews.com
#ARPA-H #biotech #Huntington's disease #RNA therapies #UniQure
